Spots Global Cancer Trial Database for diffuse
Every month we try and update this database with for diffuse cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Chemotherapy for Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma | NCT00090727 | Solid Malignanc... Non-Hodgkin's L... | AQ4N | 18 Years - | Novacea | |
| A Study to Evaluate the Safety and Efficacy of Polatuzumab Vedotin in Combination With Rituximab, Gemcitabine and Oxaliplatin Compared to Rituximab, Gemcitabine and Oxaliplatin Alone in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma | NCT04182204 | Diffuse Large B... | Polatuzumab Ved... Rituximab Gemcitabine Oxaliplatin | 18 Years - | Hoffmann-La Roche | |
| AZD1152 in Diffuse Large B-cell Lymphoma | NCT01354392 | Lymphoma | AZD1152 | 18 Years - | Oxford University Hospitals NHS Trust | |
| KPT-330 Plus RICE for Relapsed/Refractory Aggressive B-Cell Lymphoma | NCT02471911 | Diffuse Large B... | KPT-330 Rituximab Etoposide Carboplatin Ifosfamide Dexamethasone | 18 Years - | Weill Medical College of Cornell University | |
| Low-dose Radiotherapy for Diffuse Large B-cell Lymphoma | NCT02803840 | Lymphoma | Low-dose radiot... | 18 Years - | Centro di Riferimento Oncologico - Aviano | |
| Low-dose Radiotherapy for Diffuse Large B-cell Lymphoma | NCT02803840 | Lymphoma | Low-dose radiot... | 18 Years - | Centro di Riferimento Oncologico - Aviano | |
| Low-dose Radiotherapy for Diffuse Large B-cell Lymphoma | NCT02803840 | Lymphoma | Low-dose radiot... | 18 Years - | Centro di Riferimento Oncologico - Aviano | |
| KPT-330 Plus RICE for Relapsed/Refractory Aggressive B-Cell Lymphoma | NCT02471911 | Diffuse Large B... | KPT-330 Rituximab Etoposide Carboplatin Ifosfamide Dexamethasone | 18 Years - | Weill Medical College of Cornell University | |
| AZD1152 in Diffuse Large B-cell Lymphoma | NCT01354392 | Lymphoma | AZD1152 | 18 Years - | Oxford University Hospitals NHS Trust | |
| A Study to Evaluate the Safety and Efficacy of Polatuzumab Vedotin in Combination With Rituximab, Gemcitabine and Oxaliplatin Compared to Rituximab, Gemcitabine and Oxaliplatin Alone in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma | NCT04182204 | Diffuse Large B... | Polatuzumab Ved... Rituximab Gemcitabine Oxaliplatin | 18 Years - | Hoffmann-La Roche | |
| A Study to Evaluate the Safety and Efficacy of Polatuzumab Vedotin in Combination With Rituximab, Gemcitabine and Oxaliplatin Compared to Rituximab, Gemcitabine and Oxaliplatin Alone in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma | NCT04182204 | Diffuse Large B... | Polatuzumab Ved... Rituximab Gemcitabine Oxaliplatin | 18 Years - | Hoffmann-La Roche | |
| Brentuximab Vedotin in CD30 Positive Epstein Barr Virus (EBV) Positive DLBCL of Elderly | NCT01671813 | Lymphoma | brentuximab ved... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
